Glenmark Generics Launch @ Risk: Case Study Analysis
This paper analyzes the Glenmark Generics Inc. launch @ risk case study, evaluating four strategic options available to the company: proceeding with the launch at risk, taking out an insurance policy, foregoing the launch entirely, and negotiating a settlement with Sanofi-Aventis. Drawing on projected sales revenues, gross profit margins, industry-wide litigation trends, and insurance premium estimates, the paper assesses the financial and legal risks of each option. The analysis concludes that negotiating a pay-for-delay settlement with Sanofi-Aventis represents the least risky and most financially sound course of action for Glenmark.
- Introduction and Overview of Options: Four risk-management options facing Glenmark introduced
- Proceeding with the Launch @ Risk: Financial rewards and litigation risks evaluated
- Taking Out an Insurance Policy for Launch @ Risk: Insurance premium costs versus projected revenues compared
- Foregoing the Launch @ Risk: Impact of abandoning launch on revenues and competition
- Negotiating a Settlement with Sanofi-Aventis: Pay-for-delay settlement assessed as least risky option
- Conclusion: Settlement with Sanofi-Aventis recommended as best strategy
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper systematically evaluates each strategic option using consistent financial logic, grounding claims in specific numerical projections (e.g., $18.9 million projected revenue, 38% insurance premium estimate) rather than general assertions.
- It situates Glenmark's decision within broader industry context by referencing litigation trends and legal track records, adding credibility to the risk assessments.
- The conclusion flows logically from the comparative analysis, making it easy for readers to follow the reasoning from problem to recommendation.
Key academic technique demonstrated
The paper demonstrates structured comparative analysis — a core technique in business case studies — by presenting each option as a discrete section with its own risk profile, financial projections, and verdict before synthesizing findings into a final recommendation. This parallel structure makes trade-offs immediately visible and aids persuasiveness.
Structure breakdown
The paper opens with a brief framing of the four options, then dedicates one section to each alternative, moving from most complex (proceed with litigation) to simplest (forego entirely) before closing with the preferred option (settlement). A one-sentence conclusion restates the recommendation. The structure mirrors a standard business decision memo format, appropriate for an undergraduate case study response.
Introduction and Overview of Options
Glenmark Generics Inc. faces four risk-management options regarding its potential launch at risk: to proceed with the launch @ risk, to negotiate with Sanofi-Aventis for a settlement, to take out an insurance policy for the launch @ risk, and to forego the launch @ risk altogether. The sections below discuss the risks associated with each of these options in order to identify the most plausible course of action for the company.
Proceeding with the Launch @ Risk
In determining whether to proceed with the launch @ risk, Glenmark would need to consider the risks involved in navigating the legal maze and the possible effects of litigation on pricing and gross margins. The company had committed an initial capital outlay of $0.5 million in developing Tarka. Sales revenues are projected at $18.9 million during the six-month exclusivity period, assuming the worst-case scenario that it sells 10 percent fewer units than the projected 10 million capsules at a unit price of $2.10 (9 million units × $2.10). This would translate to a gross profit margin of 97 percent of sales (gross profit of $18.4 million / $18.9 million). Thus, the company stands to earn a substantial financial reward from this option.
However, the risk of financial loss arising from patent infringement litigation is high, since the company would have to settle with Sanofi-Aventis in the event that it loses the case. Looking at the industry-wide litigation trends shown in Exhibit 4, launches @ risk are less popular than settlements and generics authorized by manufacturers, suggesting they carry greater risk relative to the other two options. Furthermore, the industry-wide legal track record indicates that Glenmark has an almost 50 percent chance of losing, in which case it would have to pay damages to Sanofi-Aventis determined by the volume of sales. Glenmark could attempt to minimize the damages it would owe by selling fewer units at a higher price. However, the feasibility of this plan is limited because the patented manufacturer's price is $3 per capsule, and pricing the generic closer to that level would significantly reduce both sales volume and profit margins.
Taking Out an Insurance Policy for Launch @ Risk
Glenmark could choose to proceed with the launch @ risk while taking out an insurance policy to minimize financial exposure in the event of losing the case. An insurer would set the premium based on the jurisdiction of the court and its past rulings. While New Jersey courts appear relatively favorable to generic manufacturers, both the industry track record and Glenmark's own history point to a 48 to 50 percent chance of success — an almost equal probability of failure. An insurer would therefore likely set the premium at between 35 and 38 percent of gross profit.
Assuming the worst-case scenario in which the premium is pegged at 38 percent of the gross profit, or profit before income and taxes of $140.04 million as per the income statement, Glenmark would pay approximately $53 million in premiums (38% × $140.04 million). The maximum sales the company could realistically expect from the launch @ risk, assuming sales of 11 million capsules, is $23.1 million (11 million units × $2.10) — a figure considerably lower than the $53 million it would pay in premiums to eliminate the financial risk. Thus, taking out an insurance policy for the launch @ risk does not appear to be a viable option. For further context on how the Hatch-Waxman Act shapes generic drug exclusivity and litigation dynamics, the broader regulatory environment is an important consideration.
Conclusion
In conclusion, it would be appropriate for Glenmark to negotiate a settlement with Sanofi-Aventis, as this is the least risky alternative among the four and has the least adverse effect on the company's profit margins.
References
Chandasekhar, R. (2021). Glenmark Generics Inc.: Launch @ risk. Ivey Publishing.
Always verify citation format against your institution’s current style guide requirements.